|
United Kingdom Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The United Kingdom Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the United Kingdom .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the British pharmaceutical and healthcare industry.
Competitive intelligence, British pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the British market.
The United Kingdom Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s United Kingdom Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the British pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the United Kingdom to test other views – a key input for successful budgeting and strategic business planning in the British pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the British Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the United Kingdom .
- Exploit The Latest Competitive British Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the United Kingdom .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
United Kingdom Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| UK Pharmaceuticals And Healthcare Industry SWOT |
| United Kingdom Political SWOT |
| United Kingdom Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceuticals Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - UK – Market Summary |
| Regulatory Regime |
| Recent NICE Recommendations |
| Innovative Medicines |
| Generic Medicines |
| OTC Medicines |
| Recent EU Regulatory Developments |
| Intellectual Property Issues |
| Counterfeit Pharmaceuticals |
| Table: Examples Of Recalls Of Counterfeit Medicines In The UK |
| Pricing Regime |
| Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Financing |
| Health Insurance |
| Wholesale Sector |
| Retail Sector |
| Table: Registered Pharmacy Premises In The UK (2007) |
| Parallel Imports |
| Health Tourism |
| Research and Development Sector |
| Clinical Trials |
| Biotechnology |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: UK's Drug Market Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: UK's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: United Kingdom – Macroeconomic Forecasts, 2004-2013 |
| Prescription Drug Market Forecast |
| Table: UK's Prescription Drug Market Indicators, 2004-2013 (GBPmn unless otherwise indicated) |
| OTC Market Forecast |
| Table: UK's OTC Market Indicators, 2004-2013 (GBPmn unless otherwise stated) |
| Patented Market Forecast |
| Table: UK's Patented Market Indicators Forecast, 2004-2013 |
| Generics Market Forecasts |
| Table: UK's Generics Market Indicators, 2004-2013 |
| Export/Import Forecasts |
| Table: UK's Sectoral Trade Forecast Indicators, 2004-2013 (US$mn) |
| Key Risks to BMI Forecasts |
Chapter - Competitive Landscape |
| Table: Leading Pharmaceutical Corporations in the UK by Market Share (2007) |
| Table: Top pharmaceutical products in the UK (2007) |
| Table: Cost Of Prescriptions* Dispensed In Various Disease Areas (GBPmn) |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Leading Indigenous Manufacturers |
| GlaxoSmithKline |
| AstraZeneca |
Chapter - Country Snapshot: UK Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2000-2005 |
| Table: Consumer Expenditure, 2000-2011 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
United Kingdom Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI calculates the UK’s pharmaceutical expenditure to have been GBP18.7bn (US$36.8bn) in 2008. By 2013, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have reached a value of GBP21.2bn equating to a compound annual growth rate (CAGR) of 2.5%. In US dollar terms, however, as a result of the weakening pound, drug market expenditure will fall sharply from US$36.8bn in 2008 to US$26.6bn in 2009.
In BMI’s Business Environment Rankings for 2009, the UK is placed 6th out of the 9 Western European Markets surveyed in Q209. Globally, the UK is ranked in 12th position, just behind France and South Korea, after falling one place in Q209.
In March 2009, it was revealed that the UK government is considering a proposal that will allow some doctors to sell OTC medicines to their patients for commercial gain. BMI believes that the availability of OTC medicines in dispensing practices that serve nearly 3.1mn people will help the government push pharmaceutical spending from the public to private sector. The government has been encouraging self-care in a bid to reduce the burden being placed on the National Health Service (NHS), and in recent years has taken measures such as reclassifying a number of prescription medicines to OTC status. This has been a key driver of OTC growth and has led to an increase in the number of active ingredients available in pharmacies without a prescription.
Additionally, in March 2009, the Citizen’s Council recommended that the National Institute for Health and Clinical Excellence (NICE) should be more flexible when carrying out assessments on whether an intervention should be available to the NHS. The body has rarely authorised medicines that lie above the GBP30,000 (US$42,984) threshold figure, but those that have been authorised include drugs for osteoporosis and motor neurone disease. The heavy reliance on the use of the quality-adjusted life year (QALY) measurement has caused controversy in the past. BMI welcomes an alteration in rules as this will create increased transparency in decision making and may aid communication with drugmakers and regulatory bodies.
In early 2009, it was revealed that UK Prime Minister Gordon Brown was in talks with key industry figures to discuss ways of protecting pharmaceuticals and biotechnology companies, their revenues and their jobs as the economy rapidly deteriorates. In December 2008, representatives from the UK’s biotechnology industry had called for government investment to support the sector, after it was suggested that up to one-quarter of the UK’s 400 biotech companies could go bust in 2009. BMI believes that biotechnology is not an obvious candidate for a bailout as the industry employs only about 15,000 people in the UK, compared to the automobile industry which employs several hundred thousand. Nevertheless, the sector is vitally important to the UK economy.
|
United Kingdom Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |